Predictors and Outcomes of Recurrent Stent Thrombosis

Armstrong, Ehrin J.; Sab, Shiv; Singh, Gagan D.; Lim, Wayland; Yeo, Khung‐Keong; Waldo, Stephen W.; Patel, Mitul; Reeves, Ryan; MacGregor, John S.; Low, Reginald I.; Shunk, Kendrick A.; Mahmud, Ehtisham; Rogers, Jason H.

doi:10.1016/j.jcin.2014.05.017

Cited by 29 publications

(16 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with short-term DAPT (3 or 6 months), long-term DAPT (≥12 months) significantly reduced the risk of cardiac ischemic events. 25 For patients with prior stent thrombosis, a study from Armstrong et al 26 showed that patients with an initial stent thrombosis are at high risk for recurrent stent thrombosis; thus, a longer DAPT duration for these patients may be considered.…”

Section: Discussionmentioning

confidence: 99%

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials

Guo

Dai

et al. 2018

DDDT

View full text Add to dashboard Cite

Background: The optimal dual antiplatelet therapy (DAPT) duration after second-generation drug-eluting stent (DES) implantation remains unclear. We aim to evaluate the efficacy and safety of short-term (#6 months) and long-term ($12 months) DAPT after second-generation DES implantation. Methods: Randomized controlled trials (RCTs) were searched in PubMed, the Cochrane Library, the Embase and ClinicalTrials.gov in the English language. The endpoints included allcause mortality, cardiac death, non-cardiac death, myocardial infarction (MI), stent thrombosis (ST), stroke, all bleeding, and major bleeding. The effect estimate was expressed by using the hazard ratio (HR) with 95% CI and random effect models.Results: Seven RCTs with 13,571 patients were included in this study. In terms of survival endpoints, there was no significant difference in all-cause mortality (HR: 0.91; 95% CI: 0.71-1.17), cardiac death (HR: 0.93; 95% CI: 0.67-1.29), and non-cardiac death (HR: 0.89; 95% CI: 0.62-1.28) in the 2 groups. Moreover, there was no significant difference in ischemic outcomes, including MI (HR: 1.15; 95% CI: 0.91-1.45), ST (HR: 1.11; 95% CI: 0.75-1.66), and stroke (HR: 0.85; 95% CI: 0.53-1.35) in the 2 groups. In terms of bleeding endpoints, there was no significant difference in all bleeding (HR: 0.81; 95% CI: 0.64-1.04) and major bleeding (HR: 0.82; 95% CI: 0.49-1.36) in the 2 groups. The subgroup analysis showed that the proportion of patients with acute coronary syndrome was not associated with the benefit of long-term versus short-term DAPT. Conclusion: Short-term DAPT is not inferior to long-term DAPT in patients implanted with second-generation DES.

show abstract

Section: Discussionmentioning

confidence: 99%

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials

Guo

Dai

et al. 2018

DDDT

View full text Add to dashboard Cite

show abstract

“…Armstrong et al reported on a combined retrospective and prospective observational California registry of angiographic definite stent thrombosis at five academic hospitals from 2005 to 2013. 248 The entry criterion was the occurrence of a definite stent thrombosis, which was observed in 221 patients overall out of an unknown number of patients at risk. With the important caveat of not knowing for each stent type the exact timing of the first stent thrombosis event after the index procedure, 104 (47%) patients had received a first generation DES, 51 (23%) a BMS, and 19 (9%) a second generation DES.…”

Section: Dual Antiplatelet Therapy Decision Making In Patients With Smentioning

confidence: 99%

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

Valgimigli¹,

Bueno²,

Byrne³

et al. 2017

European Heart Journal

2,285

484

View full text Add to dashboard Cite

“…Doniesienie naukowe Armstronga i wsp. [248] obejmowało połączone dane retrospektywne i prospektywne z obserwacyjnego rejestru z Kalifornii, który uwzględniał występowanie stwierdzonej angiograficznie zakrzepicy w stencie w 5 szpitalach akademickich w latach 2005-2013. Kryterium włączenia do badania było wystąpienie potwierdzonej zakrzepicy w stencie, którą rozpoznano u 221 pacjentów z nieograniczonej liczebnie grupy chorych obciążonych ryzykiem zakrzepicy.…”

Section: Podejmowanie Decyzji O Podwójnejunclassified

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

Valgimigli

Bueno²,

Byrne³

et al. 2017

Kardiol Pol

215

224

View full text Add to dashboard Cite

show abstract

Predictors and Outcomes of Recurrent Stent Thrombosis

Abstract: rST represents an important cause of long-term morbidity and mortality after an initial ST. Bifurcation ST and a larger proximal reference vessel diameter are independently associated with an increased risk of rST.

Cited by 29 publications

References 39 publications

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

Contact Info

Product

Resources

About